ALXO Stock Analysis: Why Alx Oncology Holdings  Scored 37% in Stock Value Finder

Alx Oncology Holdings (ALXO): A Detailed Educational Stock Research Review

Overview of Alx Oncology Holdings (ALXO)

Alx Oncology Holdings (ALXO) is a clinical-stage biotechnology company operating in the healthcare sector, specifically within the biotechnology industry. The company focuses on developing therapies for cancer treatment, though as an educational review, we will concentrate on the available financial metrics rather than product pipelines or clinical trial outcomes.

This article provides a detailed, number-driven analysis of ALXO based on the supplied financial data from StockValueFinder.com. Our goal is to help readers understand how to evaluate stocks using specific financial metrics, what ranges are considered strong or weak, and why ALXO received its current StockValueFinder score and rating.

At the time of this review, ALXO trades at $1.19 per share. The StockValueFinder system assigned ALXO a score of 37% and a rating of "AVOID." This rating reflects the company's current financial profile, which we will explore in detail across multiple key metrics.

Why the StockValueFinder Score Matters

The StockValueFinder score is a composite measure designed to evaluate a company's financial health, efficiency, valuation, and market trend. Scores range from 0% to 100%, with higher scores generally indicating a more attractive financial profile based on the system's criteria.

A score of 37% places ALXO in the lower range of the scoring spectrum. The "AVOID" rating suggests that, based on the available data, the stock does not meet the system's thresholds for financial strength, efficiency, or valuation discipline. However, it is important to note that this score is not a prediction of future performance. Instead, it reflects an assessment of the company's current financial metrics relative to the system's benchmarks.

Scores and ratings are tools for educational purposes, helping investors learn how to evaluate stocks systematically. They are not guarantees of success or failure, and all investments carry risk.

EPS Strength and Consistency

What Is EPS and Why Does It Matter?

Earnings per share (EPS) measures a company's profitability on a per-share basis. It is calculated by dividing net income by the number of outstanding shares. EPS is a critical metric because it provides insight into a company's ability to generate profits for its shareholders. Consistent or growing EPS over time is often a sign of a financially healthy company with a sustainable business model.

StockValueFinder's EPS Test for ALXO

The StockValueFinder system recorded that ALXO "Did not pass" the EPS test. While the exact EPS values are not supplied, the failure of this test indicates that the company's earnings history did not meet the system's criteria for consistency or profitability.

For context, StockValueFinder typically looks for a track record of positive EPS, ideally with growth over time. For example, a company with EPS of $1.00, $1.20, and $1.40 over three consecutive years demonstrates consistent profitability and growth. In contrast, a company with negative or erratic EPS may struggle to generate shareholder value.

Why ALXO Failed the EPS Test

Given that ALXO is a clinical-stage biotechnology company, it is common for such firms to report negative EPS due to high research and development (R&D) costs and a lack of commercialized products. While negative EPS is not unusual in this industry, it does indicate that the company is not yet profitable on a per-share basis. This is an important consideration for investors, as unprofitable companies often rely on external funding (e.g., equity offerings or debt) to sustain operations, which can dilute existing shareholders or increase financial risk.

ROIC and Capital Efficiency

What Is ROIC and Why Does It Matter?

Return on invested capital (ROIC) measures how effectively a company uses its capital to generate profits. It is calculated as:

ROIC = (Net Operating Profit After Taxes) / (Total Invested Capital)

ROIC is a key indicator of capital efficiency. A higher ROIC suggests that a company is generating more profit from each dollar of invested capital, which is generally a sign of a strong business model or competitive advantage.

StockValueFinder's ROIC Benchmark

StockValueFinder generally prefers companies with an ROIC of 10% or higher. For example

– A company with an ROIC of 15% is typically using its capital more efficiently than one with an ROIC of 4%. – An ROIC of 20% or higher may indicate a company with a strong competitive moat or high-quality business model.

ALXO's ROIC: -325.97%

ALXO's ROIC is -325.97%, which is significantly below the system's preferred threshold of 10%. This negative ROIC indicates that the company is not generating a positive return on its invested capital. In fact, it is losing money on its investments, which is a red flag for capital efficiency.

For comparison, consider two hypothetical companies

– Company A has an ROIC of 12%. For every $100 of invested capital, it generates $12 in profit after taxes. – Company B has an ROIC of -50%. For every $100 of invested capital, it loses $50.

ALXO's ROIC of -325.97% suggests that the company is losing $325.97 for every $100 of invested capital, which is a significant inefficiency. This is not uncommon for early-stage biotechnology companies, which often invest heavily in R&D without immediate returns. However, it does highlight the financial challenges the company faces in generating profitable growth.

Why ALXO Failed the ROIC Test

ALXO failed the ROIC test because its ROIC of -325.97% is well below the system's benchmark of 10%. This failure reflects the company's current inability to generate positive returns on its invested capital, which is a critical consideration for investors evaluating financial efficiency.

Interest Coverage and Financial Safety

What Is Interest Coverage and Why Does It Matter?

Interest coverage measures a company's ability to pay the interest on its outstanding debt. It is calculated as:

Interest Coverage = (Earnings Before Interest and Taxes) / (Interest Expense)

A higher interest coverage ratio indicates that a company is more capable of meeting its interest obligations, which reduces the risk of default. Conversely, a low or negative interest coverage ratio suggests that a company may struggle to service its debt, increasing financial risk.

StockValueFinder's Interest Coverage Benchmark

StockValueFinder typically prefers an interest coverage ratio of 6 or higher. For example: – A company with an interest coverage ratio of 8x can cover its interest expenses 8 times over with its earnings, which is generally considered healthy. – A company with an interest coverage ratio of 2x may struggle to meet its interest obligations, especially if earnings decline.

ALXO's Interest Coverage Test Result

The StockValueFinder system recorded that ALXO "Did not pass" the interest coverage test. While the exact interest coverage ratio is not supplied, the failure of this test suggests that the company's earnings (or lack thereof) are insufficient to cover its interest expenses.

For clinical-stage biotechnology companies, interest coverage can be particularly challenging. These companies often carry significant debt to fund R&D and operations, and without commercialized products, they may lack the revenue to cover interest payments. This increases financial risk, as the company may need to raise additional capital or restructure its debt to avoid default.

Why ALXO Failed the Interest Coverage Test

ALXO failed the interest coverage test, indicating that its ability to service its debt is a concern. This is an important consideration for investors, as companies with weak interest coverage ratios may face higher financial risk, especially in economic downturns or periods of rising interest rates.

Debt Payback and Balance Sheet Discipline

What Is Debt Payback and Why Does It Matter?

Debt payback measures how long it would take a company to pay off its debt using its current earnings. It is calculated as:

Debt Payback (Years) = (Total Debt) / (Annual Earnings Before Interest and Taxes)

A shorter debt payback period indicates that a company can more quickly eliminate its debt, reducing financial risk. Conversely, a longer debt payback period suggests that a company may struggle to manage its debt load, especially if earnings decline.

StockValueFinder's Debt Payback Benchmark

StockValueFinder generally prefers a debt payback period of 3 years or less. For example

– A company with a debt payback period of 1.5 years can eliminate its debt relatively quickly, which is attractive to investors. – A company with a debt payback period of 7 years may face challenges in managing its debt, especially if earnings fluctuate.

ALXO's Debt Payback: -0.05 Years

ALXO's debt payback period is -0.05 years. While this number is unusual, it reflects the company's current financial situation. A negative debt payback period typically occurs when a company has negative earnings (i.e., losses) and cannot generate the cash flow needed to pay down debt.

For context, consider two hypothetical companies

– Company A has a debt payback period of 2 years. It can pay off its debt in 2 years using its current earnings. – Company B has a debt payback period of -0.05 years. It is not generating positive earnings, so it cannot pay down its debt with current cash flow.

Why ALXO Passed the Debt Payback Test

Despite the negative debt payback period, ALXO "passed" the debt payback test. This may seem counterintuitive, but it is important to understand the context. The StockValueFinder system may have passed ALXO on this metric because the company's debt levels are relatively low compared to its cash reserves or because the system accounts for the unique financial dynamics of clinical-stage biotechnology companies.

For example, if ALXO has minimal debt and significant cash on hand, the negative debt payback period may not be as concerning as it would be for a company with high debt and no cash reserves. However, this does not eliminate the financial risk associated with negative earnings.

P/E Ratio and Valuation Discipline

What Is P/E Ratio and Why Does It Matter?

The price-to-earnings (P/E) ratio measures a company's current share price relative to its earnings per share. It is calculated as:

P/E Ratio = (Share Price) / (Earnings Per Share)

The P/E ratio is a key valuation metric, helping investors assess whether a stock is overvalued or undervalued relative to its earnings. A lower P/E ratio may indicate that a stock is undervalued, while a higher P/E ratio may suggest that it is overvalued.

StockValueFinder's P/E Benchmark

StockValueFinder generally prefers a P/E ratio of 15 or lower for valuation discipline. For example: – A company with a P/E ratio of 8 may be considered undervalued if its business fundamentals are strong. – A company with a P/E ratio of 40 may be considered overvalued, especially if its earnings growth does not justify the premium.

ALXO's P/E Ratio: -0.70

ALXO's P/E ratio is -0.70. A negative P/E ratio occurs when a company reports negative earnings (i.e., losses). In such cases, the P/E ratio is not meaningful in the traditional sense, as it cannot be used to assess valuation relative to earnings.

For example

– Company A has a P/E ratio of 12. Its share price is 12 times its earnings, which may be reasonable if its business is growing. – Company B has a P/E ratio of -0.70. Its share price cannot be meaningfully compared to its earnings because it is not generating profits.

Why ALXO Passed the P/E Valuation Test

ALXO "passed" the P/E valuation test despite its negative P/E ratio. This may reflect the system's recognition that negative P/E ratios are common for early-stage biotechnology companies, which often prioritize growth and R&D over profitability. However, it is important to note that a negative P/E ratio does not indicate value in the traditional sense. Instead, it highlights the company's current lack of profitability.

Moving Average Trend and Entry Timing

What Is the Moving Average Trend and Why Does It Matter?

The moving average trend is a technical indicator that helps investors assess the direction of a stock's price movement over time. It is calculated by averaging the stock's price over a specific period (e.g., 50-day or 200-day moving average). A stock trading above its moving average may be in an uptrend, while a stock trading below its moving average may be in a downtrend.

StockValueFinder's Moving Average Signal for ALXO

The StockValueFinder system assigned ALXO a moving average signal of "SELL / AVOID TREND." This signal suggests that the stock is currently in a downtrend based on its moving average analysis. It is important to note that this signal is not a prediction of future performance but rather an assessment of the stock's recent price action.

For example

– A stock with a "BUY" moving average signal may be trading above its 50-day and 200-day moving averages, indicating upward momentum. – A stock with a "SELL / AVOID TREND" signal may be trading below its moving averages, indicating downward momentum.

Why the Moving Average Signal Matters for ALXO

ALXO's "SELL / AVOID TREND" signal reflects the stock's recent price weakness. While this does not guarantee that the stock will continue to decline, it does suggest that the stock is not currently exhibiting upward momentum. Investors using technical analysis may view this as a reason to exercise caution or avoid the stock until the trend improves.

Overall Financial Strengths and Weaknesses

Strengths

1. **Debt Payback Test Passed**: ALXO passed the debt payback test, which may indicate that its debt levels are manageable relative to its cash reserves or financial flexibility. This is a positive sign for balance sheet discipline, though it is important to consider the context of negative earnings. 2. **P/E Valuation Test Passed**: While ALXO's negative P/E ratio is not meaningful in the traditional sense, the system passed the stock on this metric, likely recognizing the unique financial dynamics of clinical-stage biotechnology companies.

Weaknesses

1. **EPS Test Failed**: ALXO did not pass the EPS test, reflecting its lack of profitability. This is a significant weakness, as consistent earnings are a key indicator of financial health. 2. **ROIC Test Failed**: ALXO's ROIC of -325.97% is a major red flag for capital efficiency. The company is not generating positive returns on its invested capital, which is a critical concern for long-term financial sustainability. 3. **Interest Coverage Test Failed**: ALXO did not pass the interest coverage test, indicating potential challenges in servicing its debt. This increases financial risk, especially if the company cannot generate positive cash flow in the future. 4. **Moving Average Signal**: The "SELL / AVOID TREND" signal suggests that the stock is currently in a downtrend, which may deter investors looking for upward momentum.

Risks and Limitations

Financial Risks

1. **Negative Earnings and Cash Flow**: ALXO's lack of profitability and negative ROIC highlight the financial risks associated with investing in a clinical-stage biotechnology company. Without commercialized products, the company may continue to rely on external funding, which can dilute shareholders or increase debt levels. 2. **Debt and Interest Obligations**: While ALXO passed the debt payback test, its failure of the interest coverage test suggests that servicing debt could become a challenge if earnings do not improve. This increases the risk of financial distress. 3. **Capital Efficiency**: ALXO's negative ROIC indicates that the company is not efficiently using its capital to generate returns. This is a significant risk, as it may struggle to attract investors or secure additional funding if it cannot demonstrate progress toward profitability.

Industry-Specific Risks

1. **Clinical and Regulatory Risks**: As a biotechnology company, ALXO faces significant clinical and regulatory risks. The success of its drug development programs is uncertain, and failure to achieve regulatory approval could have a material impact on its financial prospects. 2. **Market Competition**: The biotechnology industry is highly competitive, with many companies developing therapies for similar indications. ALXO may face challenges in differentiating its products or achieving market adoption, even if its therapies are successful in clinical trials. 3. **Funding Risks**: Clinical-stage biotechnology companies often rely on external funding to sustain operations. If ALXO cannot secure additional funding through equity offerings, debt, or partnerships, it may face liquidity challenges that could jeopardize its ability to continue operations.

Limitations of This Analysis

1. **Lack of Detailed Financial Data**: This analysis is based on the supplied financial metrics, which do not include detailed EPS history, cash flow statements, or balance sheet items. A more comprehensive review would require additional data to assess ALXO's financial health fully. 2. **Focus on Quantitative Metrics**: This review focuses on quantitative financial metrics and does not consider qualitative factors such as management quality, pipeline potential, or competitive positioning. These factors can also play a significant role in a company's long-term success. 3. **No Future Predictions**: This analysis does not predict ALXO's future performance or the success of its drug development programs. Investors should conduct their own research and consider the risks before making investment decisions.

Educational Conclusion

This educational review of Alx Oncology Holdings (ALXO) provides a detailed analysis of the company's financial metrics based on the data supplied by StockValueFinder.com. The goal of this article is to help readers understand how to evaluate stocks using specific financial benchmarks, what ranges are considered strong or weak, and why ALXO received its current StockValueFinder score and rating.

Key Takeaways for Investors

1. **EPS and Profitability**: ALXO did not pass the EPS test, reflecting its lack of profitability. Investors should consider whether the company can achieve profitability in the future and how this might impact its financial health. 2. **ROIC and Capital Efficiency**: ALXO's ROIC of -325.97% is a significant red flag for capital efficiency. The company is not generating positive returns on its invested capital, which is a critical concern for long-term financial sustainability. 3. **Interest Coverage and Debt**: ALXO failed the interest coverage test, indicating potential challenges in servicing its debt. While it passed the debt payback test, investors should monitor the company's debt levels and cash flow to assess financial risk. 4. **P/E Ratio and Valuation**: ALXO's negative P/E ratio is not meaningful in the traditional sense, but it highlights the company's current lack of profitability. Investors should consider whether the company's pipeline and growth prospects justify its valuation. 5. **Moving Average Trend**: ALXO's "SELL / AVOID TREND" signal suggests that the stock is currently in a downtrend. Investors using technical analysis may view this as a reason to exercise caution.

Final Thoughts

ALXO's StockValueFinder score of 37% and "AVOID" rating reflect its current financial profile, which includes significant weaknesses in profitability, capital efficiency, and interest coverage. While the company passed the debt payback and P/E valuation tests, these results should be interpreted in the context of its negative earnings and ROIC.

Investors considering ALXO should weigh the potential rewards of investing in a clinical-stage biotechnology company against the significant financial risks. It is also important to conduct additional research, including a review of the company's pipeline, competitive positioning, and management team, before making any investment decisions.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

---

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings